<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131677</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHHSTP-4323</org_study_id>
    <nct_id>NCT00131677</nct_id>
  </id_info>
  <brief_title>Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men</brief_title>
  <official_title>Phase II Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>San Francisco Department of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS Research Consortium of Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine safety and tolerability of daily tenofovir use in
      HIV-uninfected men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the clinical and behavioral safety and tolerability of oral daily TDF
      use as pre-exposure prophylaxis (PrEP) to prevent HIV infection in uninfected men.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Safety--Creatinine Elevations</measure>
    <time_frame>24 months (immediate arm) and 15 months (delayed arm)</time_frame>
    <description>Grade 3 or 4 Creatinine elevations (per National Institutes of Health Division of AIDS toxicity scale)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Safety--Hypophosphatemia</measure>
    <time_frame>24 months (immediate arm), 15 months (delayed arm)</time_frame>
    <description>Grade 3 or 4 hypophosphatemia (per National Institutes of Health Division of AIDS toxicity scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Breakthrough HIV Infections</measure>
    <time_frame>24 months (immediate arm) and 15 months (delayed arm)</time_frame>
    <description>Number of participants with HIV seroconversions occuring while on study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Study Drug</measure>
    <time_frame>24 months (immediate arm) and 15 months (delayed arm)</time_frame>
    <description>Estimated exposure to study drug (active and placebo) as assessed by Medication Event Monitoring System (MEMS) caps.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Safety--Unprotected Anal Sex (UAS)</measure>
    <time_frame>Nine months</time_frame>
    <description>Change in percent of participants reporting unprotected anal intercourse--baseline vs. months 3 through 9 on study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>&gt;5% Bone Mineral Density Decline at Femoral Neck</measure>
    <time_frame>24 months (immediate arm), 15 months (delayed arm)</time_frame>
    <description>Percent of San Francisco participants in the TDF vs. placebo groups who were found to have &gt;5% decline in Bone Mineral Density at the femoral neck.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>active immediate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants in this arm start study product immediately upon enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo immediate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants in this arm start study product immediately upon enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active delayed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>persons in this arm start study product 9 months after enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo delayed</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants in this arm start study product nine months after enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir disoproxil fumarate</intervention_name>
    <description>study product taken daily</description>
    <arm_group_label>active immediate</arm_group_label>
    <arm_group_label>active delayed</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>study product taken daily</description>
    <arm_group_label>placebo immediate</arm_group_label>
    <arm_group_label>placebo delayed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy biologic male (male at birth)

          -  18-60 years of age

          -  HIV-1 negative by licensed, commercially available, FDA-approved whole blood rapid
             enzyme immunoassay (EIA) at screening and enrollment

          -  Reports any anal sex with a man in the last 12 months

          -  Able to understand and pass comprehension assessment questionnaire

          -  Able to understand and sign a written informed consent form, which must be obtained
             prior to initiation of study procedures

          -  Able to understand English

          -  Adequate renal function: calculated creatinine clearance of at least 70 mL/min

          -  Hepatic transaminases (AST and ALT) less than or equal to 2x upper limit of normal
             (ULN)

          -  Total bilirubin less than or equal to 1.5 mg/dL

          -  Absolute neutrophil count at least 1,500/mm3;

          -  Platelets at least 100,000/mm3;

          -  Hemoglobin at least 9.5 g/dL

          -  Serum amylase less than or equal to 1.5 x ULN

          -  Biochemical profile: within normal limits for serum phosphorus, potassium, sodium, and
             calcium.

          -  Hepatitis B surface antigen negative

          -  Normal urine dipstick or urinalysis (UA)

        Exclusion Criteria:

          -  Active untreated syphilis

          -  Current uncontrolled hypertension (blood pressure &gt; 160/100 mmHg)

          -  Mutually monogamous for &gt; one year with a known HIV antibody negative partner

          -  History of chronic renal disease, known osteoporosis, osteomalacia, or osteopenia

          -  Current or expected participation in other longitudinal HIV behavioral or biomedical
             research study

          -  Current HIV antiretroviral use

          -  Receiving or planning to receive on-going therapy with any nephrotoxic agents or
             experimental/investigational agents

          -  Previous or expected requirements for the administration of immunosuppressive/
             immunomodulatory therapy (e.g. chronic systemic steroids, interferon, interleukins,
             chemotherapy, radiation).

          -  Evidence of a gastrointestinal malabsorption syndrome or chronic nausea or vomiting
             which may confer an inability to receive an orally administered medication.

          -  Current alcohol or substance abuse judged by the investigator to potentially interfere
             with participant compliance.

          -  Imminently life-threatening medical conditions (malignancy, immunosuppressive disease
             [e.g. lymphoma]), or other serious disease or conditions (e.g. cardiovascular, renal,
             diabetes) within the last 5 years or that are unstable and/or require chronic
             medication that would impede compliance with study requirements and complicate the
             interpretation of adverse events

          -  Expected to be non-compliant with study visits or planning to move within 24 months to
             an area where the study will not be conducted

          -  Any other clinical or social condition, prior therapy, occupation, or other
             responsibility, that, in the opinion of the investigator, would interfere with, or
             serve as a contraindication to study participation or compliance with the dosing
             requirements.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kata L Chillag, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa A Grohskopf, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Buchbinder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Francisco Dept. of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melanie Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Research Consortium of Atlanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth H. Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fenway Community Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Department of Public Health</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Community Health</name>
      <address>
        <city>Boston,</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2005</study_first_submitted>
  <study_first_submitted_qc>August 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2005</study_first_posted>
  <results_first_submitted>August 8, 2013</results_first_submitted>
  <results_first_submitted_qc>January 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2014</results_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in 1/2005 and was completed in 7/2007. Participant follow-up was completed in July 2009.
Participants were recruited from:
San Francisco Dept. of Public Health AIDS Research Consortium of Atlanta Fenway Health</recruitment_details>
      <pre_assignment_details>After an initial screening visit, participants were required to meet all enrollment criteria again at the enrollment visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tenofovir Disoproxil Fumarate</title>
          <description>Participants received TDF 300mg orally daily for 24 months (immediate arm) or 15 months (delayed arm).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received matching placebo, to be taken daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201">201 randomized to active drug; 101 to start immediately and 100 after a 9 month delay.</participants>
                <participants group_id="P2" count="199">199 randomized to placebo; 99 to start immediately and 100 after a 9 month delay.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>400 participants enrolled (200 in San Francisco, 121 in Atlanta, and 79 in Boston). 201 were randomized to TDF and 199 to placebo. Participants were distributed similarly in terms of age, ethnicity, education, no. male partners in previous 3 mo., and no. of unprotected anal sexual contacts within the previous 3 mo.</population>
      <group_list>
        <group group_id="B1">
          <title>Tenofovir Disoproxil Fumarate</title>
          <description>Active arm: assigned to take TDF, 300mg po daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo arm--received matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="199"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="9.3"/>
                    <measurement group_id="B2" value="36.7" spread="11.0"/>
                    <measurement group_id="B3" value="37.7" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Safety--Creatinine Elevations</title>
        <description>Grade 3 or 4 Creatinine elevations (per National Institutes of Health Division of AIDS toxicity scale)</description>
        <time_frame>24 months (immediate arm) and 15 months (delayed arm)</time_frame>
        <population>For biomedical outcomes, a treatment emergent cohort was defined. Participants entered the TE cohort with first dispense and exited with the first occurrence of: (1) completion of follow-up, (2) 30 days after permanent drug interruption, or (3) 30 days after last visit. For delayed arm participants,time before initiation of drug was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate</title>
            <description>TDF, 300 mg orally daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Safety--Creatinine Elevations</title>
          <description>Grade 3 or 4 Creatinine elevations (per National Institutes of Health Division of AIDS toxicity scale)</description>
          <population>For biomedical outcomes, a treatment emergent cohort was defined. Participants entered the TE cohort with first dispense and exited with the first occurrence of: (1) completion of follow-up, (2) 30 days after permanent drug interruption, or (3) 30 days after last visit. For delayed arm participants,time before initiation of drug was excluded.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Breakthrough HIV Infections</title>
        <description>Number of participants with HIV seroconversions occuring while on study drug</description>
        <time_frame>24 months (immediate arm) and 15 months (delayed arm)</time_frame>
        <population>For biomedical outcomes, a treatment emergent cohort was defined which included only those participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate</title>
            <description>TDF, 300 mg orally daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Breakthrough HIV Infections</title>
          <description>Number of participants with HIV seroconversions occuring while on study drug</description>
          <population>For biomedical outcomes, a treatment emergent cohort was defined which included only those participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Study Drug</title>
        <description>Estimated exposure to study drug (active and placebo) as assessed by Medication Event Monitoring System (MEMS) caps.</description>
        <time_frame>24 months (immediate arm) and 15 months (delayed arm)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Emergent Cohort</title>
            <description>Includes all who entered treatment emergent cohort (active and placebo arms)</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Study Drug</title>
          <description>Estimated exposure to study drug (active and placebo) as assessed by Medication Event Monitoring System (MEMS) caps.</description>
          <units>percentage of doses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Behavioral Safety--Unprotected Anal Sex (UAS)</title>
        <description>Change in percent of participants reporting unprotected anal intercourse--baseline vs. months 3 through 9 on study.</description>
        <time_frame>Nine months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Enrolled Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Behavioral Safety--Unprotected Anal Sex (UAS)</title>
          <description>Change in percent of participants reporting unprotected anal intercourse--baseline vs. months 3 through 9 on study.</description>
          <units>percentage of ppts reporting UAS</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Safety--Hypophosphatemia</title>
        <description>Grade 3 or 4 hypophosphatemia (per National Institutes of Health Division of AIDS toxicity scale)</description>
        <time_frame>24 months (immediate arm), 15 months (delayed arm)</time_frame>
        <population>For biomedical outcomes, a treatment emergent cohort was defined which included only those participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate</title>
            <description>Active arm: assigned to take TDF, 300mg po daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm--received matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Safety--Hypophosphatemia</title>
          <description>Grade 3 or 4 hypophosphatemia (per National Institutes of Health Division of AIDS toxicity scale)</description>
          <population>For biomedical outcomes, a treatment emergent cohort was defined which included only those participants who received study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>&gt;5% Bone Mineral Density Decline at Femoral Neck</title>
        <description>Percent of San Francisco participants in the TDF vs. placebo groups who were found to have &gt;5% decline in Bone Mineral Density at the femoral neck.</description>
        <time_frame>24 months (immediate arm), 15 months (delayed arm)</time_frame>
        <population>For biomedical outcomes, a treatment emergent cohort was defined which included only those participants who received study drug. In addition, this analysis population includes only those participants for whom bone density analyses were performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate</title>
            <description>Active arm: assigned to take TDF, 300mg po daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm--received matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>&gt;5% Bone Mineral Density Decline at Femoral Neck</title>
          <description>Percent of San Francisco participants in the TDF vs. placebo groups who were found to have &gt;5% decline in Bone Mineral Density at the femoral neck.</description>
          <population>For biomedical outcomes, a treatment emergent cohort was defined which included only those participants who received study drug. In addition, this analysis population includes only those participants for whom bone density analyses were performed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Maximum time period on drug of 24 months for immediate arm participants and 15 months for delayed arm participants.</time_frame>
      <desc>Treatment emergent cohort: participants enter cohort when study drug is initiated, and exit at the first occurence of one of these events: 1) completion of study visits, 2)30 days after loss to follow up, or 3)30 days after start of permanent drug interruption.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tenofovir Disoproxil Fumarate</title>
          <description>Active arm: assigned to take TDF, 300mg po daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="186"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="42" subjects_affected="33" subjects_at_risk="186"/>
                <counts group_id="E2" events="57" subjects_affected="45" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="186"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="123" subjects_affected="70" subjects_at_risk="186"/>
                <counts group_id="E2" events="127" subjects_affected="67" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="186"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="186"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="186"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="186"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="187"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="187"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All presentations and publications of data from CDC funded studies are subject to CDC clearance prior to publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Taraz Samandari</name_or_title>
      <organization>Centers for Disease Control and Prevention (CDC)</organization>
      <phone>404-639-1676</phone>
      <email>tts0@cdc.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

